Business Wire

Stats Perform and Control Risks Announce Global Sports Integrity Partnership at ABC Minds Sports Anti-Corruption Conference

Share

Today, Stats Perform, the revolutionary leader in sports AI and data, and Control Risks, the leading specialist risk consultancy, announce a unique partnership to bring best-in-class comprehensive sports integrity solutions to the market.

Through Stats Perform’s Integrity Unit, sports industry stakeholders such as rights holders, International Federations and Governing Bodies will be able to access Control Risks’ global investigative capabilities to help drive out corruption and match-fixing. Integrity units and compliance departments will have access to a full range of solutions, including forensic accounting, data analytics and traditional investigative capabilities, to manage risk or conduct investigations.

The partnership will combine Stats Perform’s offering across prevention, detection and investigation with Control Risks’ global investigative practice and experience in building resilient and compliant governance programmes. Together, they will help stakeholders ensure their integrity, anti-doping and compliance programmes are fit-for-purpose, while protecting the long-term value of their brands.

Furthermore, global sport stakeholders will be able to utilise the full suite of services the partnership has to offer, whether it is a team requiring due diligence on a potential investor, sponsor or new signing, or a business looking to partner with a new league or competition. The partnership will enable sports stakeholders to manage both sporting integrity and business risks in one place.

Nick Allan , CEO of Control Risks, said: “We are delighted to announce this exciting new partnership with Stats Perform to help the sports industry in its desire to combat the threats to its integrity posed by corruption and match-fixing. Our global investigations capabilities will enable all stakeholders, to be able to call on our support as part of their contract with Stats Perform.”

Mike Perez , COO of Stats Perform, said: “As the sports industry goes through a data revolution, our existing integrity services will benefit from complementary investigative capabilities to identify, investigate and respond to threats. We are very pleased to move forward with Control Risks who have the global capabilities to match our aspirations.”

Jonny Gray , Global Head of Sport at Control Risks, said: “This is a very exciting development as the sports industry looks for comprehensive support to combat existential threats to its integrity, trust and value. It gives Stats Perform’s clients the opportunity for a complete integrity solution.”

Jake Marsh , Head of Integrity at Stats Perform, said: “Sports stakeholders face a variety of governance and integrity challenges. Our role is not simply to help them identify and mitigate risk, but to assist in investigation and response. Our partnership with Control Risks helps us do that and provide a better, more complete service to our clients.”

About Control Risks

Control Risks is a specialist risk consulting firm that helps create secure, compliant and resilient organizations. We believe that taking risks is essential to success, so we provide the insight and intelligence you need to realize opportunities and grow.

Our experts across 34 offices bring experience in prosecution and law enforcement, accounting, management consulting, regional business intelligence, forensic technology and cyber security to advise the world’s largest multinational companies on major regulatory issues, conduct complex cross-border investigations and build robust compliance programs.

Learn more at www.controlrisk.com/sport

About Stats Perform

Stats Perform collects the richest sports data in the world and transforms it through revolutionary artificial intelligence (AI) to unlock the most in-depth insights for media and technology, betting and team performance. With company roots dating back almost 40 years, Stats Perform embraces and solves the dynamic nature of sport – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. As the leading sports data and AI company, Stats Perform works with the top global sports media, tech companies, sportsbooks, teams and leagues.

For more information, visit StatsPerform.com

Contact information

Caspar Leighton, Control Risks Global Content Director
Caspar.Leighton@controlrisks.com / +44 07712391228

Sarah Butler, Stats Perform PR Manager
Sarah.butler@statsperform.com / +44 07432631237

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed13.12.2019 21:55:00 EETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic fibrosis (CF) reimbursement agreement to include the triple combination regimen (elexacaftor, tezacaftor and ivacaftor), which is under review and pending approval by the European Medicines Agency, for all eligible patients ages 12 and older in line with the potential future licensed indication. This expands the existing agreement which had already included access to current and future Vertex medicines for people in Ireland with CF of any age who: Have one of the specified mutations as included in the KALYDECO® marketing authorization (G551D, G551S, S549R, G1244E, S1251N, G1349D, S1255P, G178R or S549N) or Are homozygous for the F508del mutation or Are heterozygous for the F508del mutation and have a specified mutation (P67L, D579G, D1

CreditLens™ Solution Receives SOC 2 Attestation Report13.12.2019 18:17:00 EETPress release

Moody’s Analytics announced today that the CreditLens software-as-a-service (SaaS) solution has received an attestation report from the American Institute of Certified Public Accountants (AICPA) System and Organization Controls (SOC 2). The SOC 2 report details the security and availability of customer data in the CreditLens SaaS solution, and denotes its adherence to the AICPA’s security and availability controls standards. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. It facilitates process automation and helps clients improve their efficiency, reduce errors, and streamline workflows. A SOC 2 report ensures that a company’s information security measures are in line with the unique parameters of today’s cloud requirements. The report addresses a service organization's controls that relate to operations and compliance, as outlined by the AICPA's Tru

CHMP Grants Positive Opinion for Expanded Use of Darzalex®▼ (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible13.12.2019 14:47:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorisation for Darzalex®▼ (daratumumab) to include the use of daratumumab in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of adult patients with newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The Positive Opinion is supported by data from Part 1 of the Phase 3 CASSIOPEIA (MMY3006) study, published in The Lancet 3 in June 2019, and presented at the 2019 American Society of Clinical Oncology (ASCO) Meeting. Additional information about this study can be found at www.ClinicalTrials.gov (NCT02541383). “Today’s Opinion takes us a step closer to offering the first daratumumab combination regimen to transplant eligible patients, redefining treatment for those people newl

Janssen Receives Positive CHMP Opinion for Expanded Use of Erleada® (apalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer13.12.2019 14:40:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending approval for expanding the use of Erleada® (apalutamide) to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).2 The CHMP’s Positive Opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the new use of apalutamide. The Positive Opinion is based on data from the Phase 3 TITAN study, which assessed the addition of apalutamide to ADT – the current standard of care in mHSPC – in a broad range of patients with mHSPC, regardless of disease volume, prior treatment with docetaxel or staging at initial diagnosis. The dual primary endpoints of the study were overall survival (OS) and radiographic progression-free survival (rPFS). Ap

German Player Karl Rupprec Wins 2019 Boyaa Poker Tournament Europe13.12.2019 12:24:00 EETPress release

On December 8, the sixth edition of the BPT (Boyaa Poker Tournament) came to an end. King's Resort in the Czech Republic celebrated this BPT Europe that enjoyed 600 cumulative participants from 20 countries. In the end, Karl Rupprec, from Germany, won the Main Event Championship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005109/en/ (Photo: Business Wire) Highlights of the BPT Europe 2019 final The BPT Europe 2019 Main Event began on December 8 at 2:00 p.m., Czech Republic time. After 9 hours of Texas Poker, players Ondrej Drozd from the Czech Republic and Karl Rupprec from Germany reached the last heads-up. In the end, Karl Rupprec, who started with half of his opponent's chips, reversed the situation with his two nines, winning the championship. Heads-up Highlights: Karl Rupprec pair 9 and Ondrej Drozd 2, 5. The flop was 2, Q, 9, so Karl Rupprec got three of a kind, and Ondrej Drozd got pair 2. Rupprec pretended

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by Italian Designed Architectural Lighting Brand for Motorized Luminaire with Smart Wireless Controls13.12.2019 12:00:00 EETPress release

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED technology, announced that it has achieved smart lighting design with SunLike Series natural spectrum LEDs in cooperation with Casambi Technologies Oy (“Casambi”), a leading developer of wireless lighting control systems based on Bluetooth Low Energy (BLE), and it has been adopted for the Italian designed architectural lighting brand formalighting Ltd. (“formalighting”), a global manufacturer of Italian designed architectural lighting systems and solutions for a new product line which offers motorized luminaire with smart wireless controls. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191213005009/en/ SunLike implemented in motion lamps (Photo: Business Wire) The SunLike COB LED packages have been adopted by formalighting for the new fixtures, Moto-Zero 40 Compasso and Moto-Zero 66 Zoom, in track mounted motorized spotlight range. In this sect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom